Form 4: Sionna Therapeutics Director Sells Shares

A director of Sionna Therapeutics, Bruce Booth, reported the sale of common stock through affiliated investment funds under pre-arranged trading plans.

Summary

• Bruce Booth, a Director of Sionna Therapeutics, Inc. (SION), reported sales of common stock.
• The transactions were executed pursuant to Rule 10b5-1 trading plans adopted by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. on February 25, 2025.
• On October 3, 2025, Atlas Venture Fund XI, L.P. sold 31,198 shares of Common Stock at a weighted average price of $30 per share.
• On October 3, 2025, Atlas Venture Opportunity Fund II, L.P. sold 6,548 shares of Common Stock at a weighted average price of $30 per share.
• On October 6, 2025, Atlas Venture Fund XI, L.P. sold 9,753 shares of Common Stock at a weighted average price of $29.95 per share.
• On October 6, 2025, Atlas Venture Opportunity Fund II, L.P. sold 2,047 shares of Common Stock at a weighted average price of $29.95 per share.
• Following these transactions, Atlas Venture Fund XI, L.P. beneficially owns 2,780,301 shares and Atlas Venture Opportunity Fund II, L.P. beneficially owns 785,480 shares.
• The reported prices are weighted averages, with sales occurring in ranges from $29.95 to $30.11 on October 3, 2025, and $29.95 to $30.00 on October 6, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to insider selling by a director, although the existence of a Rule 10b5-1 plan mitigates the severity by indicating pre-planned transactions rather than opportunistic selling based on immediate non-public information.

Positives

• The sales were conducted under Rule 10b5-1 trading plans, indicating they were pre-scheduled and not based on immediate, non-public information, which enhances transparency and corporate governance.

Negatives

• The sale of a significant number of shares by a director, even if planned, can be interpreted by the market as a signal of reduced conviction in the company's near-term growth prospects or a desire to diversify exposure.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported sales were made by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., in which the reporting person, Bruce Booth, is a member of their respective general partners. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders may interpret the director's sales as a negative signal, potentially impacting investor confidence and the company's stock price.

Key Dates

Recommendation

While insider selling, even under a Rule 10b5-1 plan, can be a negative signal, the pre-arranged nature of these transactions suggests they are not based on immediate adverse news. Without additional fundamental information or a clear change in company prospects, a 'hold' recommendation is appropriate, advising investors to monitor future developments and company performance closely.

Keywords

Sionna Therapeutics, SION, Form 4, insider trading, stock sale, director, Bruce Booth, Atlas Venture, 10b5-1 plan